Phibro Animal Health (PAHC) shares soared 10.2% in the last trading session to close at $20.94. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1% gain over the past four weeks. Phibro scored a strong price increase, on investors' optimism driven by its impending fiscal fourth-quarter 2024 financial results, which is slated to be released on Aug 28 post the closing bell. The Zacks Consensus Estimate for the fourth quarter revenue ...

The upcoming report from Phibro Animal Health (PAHC) is expected to reveal quarterly earnings of $0.34 per share, indicating a decline of 10.5% compared to the year-ago period. Analysts forecast revenues of $262.44 million, representing an increase of 2.9% year over year. Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. Prior to a comp ...

Phibro Animal Health (PAHC) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 28, 2024, might help the stock move higher if these key numbers are better ...

The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Most Powerful Force Impacting Stock Prices Harnessing the Power of Earnings Estimate Revisions Earnings Estimate Revisions for Phibro Bottom Line The upgrade of Phibro to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. One company to watch right now is Phibro Animal Health (PAHC) . PAHC is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. The stock is trading with a P/E ratio of 12.62, which compares to its ind ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely o ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being un ...

Have you looked into how Phibro Animal Health (PAHC) performed internationally during the quarter ending March 2024? Considering the widespread global presence of this maker of animal health products and nutritional supplements, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall fin ...

Financial Performance - Q3 FY24 (Consolidated) - Total consolidated net sales increased by 7% year-over-year, from $245.7 million to $263.2 million[24] - Adjusted EBITDA increased by 9% year-over-year, from $27.4 million to $29.7 million[24] - Net income decreased by 16% year-over-year, from $10.0 million to $8.4 million[24] - Adjusted net income increased by 9% year-over-year, from $11.6 million to $12.7 million[24] Financial Performance - Q3 FY24 (Animal Health) - Animal Health net sales increased by 10% year-over-year, from $164.4 million to $181.3 million[27] - Vaccines sales increased by 26% year-over-year[7, 27] - MFAs (Medicated Feed Additives) and other sales increased by 16% year-over-year[7, 27] - Nutritional specialties sales decreased by 11% year-over-year[7, 27] - Animal Health adjusted EBITDA increased by 7% year-over-year, from $34.2 million to $36.5 million[27] Acquisition and Guidance - The company is set to acquire Zoetis' MFA and certain water-soluble products business for $350 million, subject to adjustments[7] - The company affirms fiscal year 2024 guidance with net sales of $980 million to $1.020 billion and adjusted EBITDA of $106 million to $112 million[7]

Highlights for the three months ended March 31, 2024 (compared to the three months ended March 31, 2023) Exhibit 99.1 For Immediate Release Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance TEANECK, N.J., May 8, 2024 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) ("Phibro" or the "Company") today announced financial results for its third quarter ended March 31, 2024 and its updated financial guidance for the year ending June 30, 2024. We affirm our ...